Description: World High Life Plc formerly known as World High Life Limited, is a private equity and venture capital firm specializing in acquisition, early stage and mature companies. It may invest as debt or equity, in either quoted or unquoted securities, and made by direct acquisition of an interest in companies, partnerships or joint ventures, or direct interests in projects, or by way of licensing arrangements. It typically invests in companies operating in the Cannabidiol (CBD) wellness and medicinal cannabis, hemp including the industrial hemp with focus on therapeutic cannabis derivatives including nutraceuticals, dietary supplements and cosmetic products. The firm also seeks to invest in the cultivation of cannabis and hemp, the manufacture and distribution of medicinal cannabis, hemp and CBD products, pharmacology commercialization of medicinal cannabis, hemp and CBD, professional prescription by practitioners and after care as it relates to medicinal cannabis, statistical management, laboratory testing and compliance in respect of medicinal cannabis, hemp and CBD sectors, and the development of CBD within the wellness sector including retail products such as patches, topical ointments, tinctures, beverages, powdered supplements as well as vaping capsules, e-liquids and oils. The firm typically invests in Europe, Canada, Africa and South America, Israel and Asia. The firm will hold investments for the medium to long term, although where opportunities exist for shorter-term investments, it may undertake such investments. The firm typically acquire control in certain situations, although it may also consider acquiring non-controlling positions. The firm seeks to take majority stake. World High Life Plc was founded on 30th January 2019 and is based in London, United Kingdom.
Home Page: www.worldhighlife.uk
7-9 Swallow Street
London,
W1B 4DE
United Kingdom
Phone:
44 2039 785 322
Officers
| Name | Title |
|---|---|
| Mr. Antonio Luigi Calamita | Founder, CEO & MD |
| Mr. Anthony Dyer | Director & Interim CFO |
| James Martin | Chief Operating Officer |
| Ms. Anna Rebecca Legge | Chief Communications Officer |
| Mr. Stephen White | Chief Marketing Officer |
| Mr. Steve Horan | Head of Marketing |
| Mr. Martin Healy | Chief Growth Officer |
| Adam Pritchard | Chief Commercial Officer |
| Mr. Ian Munzberger | Chief Brand & Partnerships Officer |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.0107 |
| Price-to-Sales TTM: | 1.1516 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 28 |